NCT05390515RecruitingPhase 4
Psoriatic Immune Response to Tildrakizumab
Source: ClinicalTrials.gov · Last updated 4 Jun 2026
Brief summary (registry, in English)
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 20 May 2022
- Start date
- 1 Sept 2022
- Primary completion date
- 1 Sept 2028
- Lead sponsor
- University of California, San Francisco
- Diseases
- Psoriasis
- NCT number
- NCT05390515
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 10
- From 1 Sept 2022 to the primary completion date, 1 Sept 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- tuberculosis or other active serious infection
- active systemic malignancy.
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Other
- taking systemic immunosuppressives in the last 4 weeks
- pregnancy
- severe immunodeficiency (either from genetic or infectious causes).
- breast-feeding
Who the study is looking for
- 18 years of age or older
- Patients with moderate-severe psoriasis or \> 5% body surface area affected.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of California San Francisco Coordinator of this site? Confirm its status | San Francisco | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.